Tectonic Therapeutic Inc
TECX20.720USD
-0.010-0.05%
交易中 （美东）报价延迟15分钟
386.87M总市值
亏损市盈率 TTM
关于 Tectonic Therapeutic Inc 公司
Tectonic Therapeutic, Inc. 是一家生物技术公司。该公司专注于发现和开发调节 G 蛋白偶联受体 (GPCR) 活性的治疗性蛋白质和抗体。利用其名为 GEODe（专为最佳发现而设计的 GPCR）的技术平台，该公司专注于开发生物药物，以克服 GPCR 靶向药物发现的现有挑战并利用人体来改变疾病进程。该公司的领先项目 TX000045 (TX45) 是一种 Fc-松弛素融合分子，可激活 RXFP1 受体，即激素松弛素的 GPCR 靶点。TX45 正在 Ia/Ib 期临床试验中进行评估，作为治疗 2 组肺动脉高压伴射血分数保留的心力衰竭 (HFpEF) 的潜在方法。其第二个项目针对遗传性出血性毛细血管扩张症 (HHT)。
公司简介
公司代码TECX
公司名称Tectonic Therapeutic Inc
上市日期Jun 21, 2018
CEODr. Alise S. Reicin, M.D.
员工数量51
证券类型Ordinary Share
年结日Jun 21
公司地址490 Arsenal Way
城市WATERTOWN
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编02472
电话13396663320
网址https://tectonictx.com/
公司代码TECX
上市日期Jun 21, 2018
CEODr. Alise S. Reicin, M.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Alise S. Reicin, M.D.
Dr. Alise S. Reicin, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
290.25K
-0.30%
Dr. Peter Mcnamara, Ph.D.
Dr. Peter Mcnamara, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
19.53K
+344.82%
Dr. Praveen P. Tipirneni, M.D.
Dr. Praveen P. Tipirneni, M.D.
Independent Director
Independent Director
3.04K
--
Dr. Timothy A. (Tim) Springer, Ph.D.
Dr. Timothy A. (Tim) Springer, Ph.D.
Independent Director
Independent Director
--
--
Mr. Daniel Ferry
Mr. Daniel Ferry
IR Contact Officer
IR Contact Officer
--
--
Mr. Daniel Lochner
Mr. Daniel Lochner
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Terrance G. (Terry) Mcguire
Mr. Terrance G. (Terry) Mcguire
Independent Director
Independent Director
--
--
Dr. Marc Schwabish, Ph.D.
Dr. Marc Schwabish, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Mr. Phillip B. (Phil) Donenberg
Mr. Phillip B. (Phil) Donenberg
Independent Director
Independent Director
--
--
Mr. Stefan Vitorovic
Mr. Stefan Vitorovic
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Alise S. Reicin, M.D.
Dr. Alise S. Reicin, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
290.25K
-0.30%
Dr. Peter Mcnamara, Ph.D.
Dr. Peter Mcnamara, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
19.53K
+344.82%
Dr. Praveen P. Tipirneni, M.D.
Dr. Praveen P. Tipirneni, M.D.
Independent Director
Independent Director
3.04K
--
Dr. Timothy A. (Tim) Springer, Ph.D.
Dr. Timothy A. (Tim) Springer, Ph.D.
Independent Director
Independent Director
--
--
Mr. Daniel Ferry
Mr. Daniel Ferry
IR Contact Officer
IR Contact Officer
--
--
Mr. Daniel Lochner
Mr. Daniel Lochner
Chief Financial Officer
Chief Financial Officer
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月22日 周二
更新时间: 7月22日 周二
持股股东
股东类型
持股股东
持股股东
占比
Springer Timothy A
23.68%
Fidelity Management & Research Company LLC
14.99%
Deep Track Capital LP
7.51%
TAS Partners, L.L.C.
7.41%
EcoR1 Capital, LLC
5.01%
Other
41.40%
持股股东
持股股东
占比
Springer Timothy A
23.68%
Fidelity Management & Research Company LLC
14.99%
Deep Track Capital LP
7.51%
TAS Partners, L.L.C.
7.41%
EcoR1 Capital, LLC
5.01%
Other
41.40%
股东类型
持股股东
占比
Individual Investor
27.37%
Hedge Fund
24.98%
Investment Advisor
22.57%
Corporation
10.93%
Investment Advisor/Hedge Fund
7.56%
Venture Capital
2.74%
Research Firm
2.25%
Pension Fund
0.12%
Family Office
0.05%
Other
1.43%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
178
18.44M
98.77%
+1.52M
2025Q1
184
18.15M
106.94%
+1.93M
2024Q4
153
13.88M
94.13%
+369.61K
2024Q3
148
13.13M
89.69%
+166.42K
2024Q2
151
11.92M
81.47%
+8.19M
2024Q1
179
2.57M
67.87%
-1.12M
2023Q4
200
2.14M
56.67%
-1.83M
2023Q3
236
2.28M
60.58%
-1.25M
2023Q2
243
1.76M
47.84%
-1.94M
2023Q1
262
2.00M
54.58%
-1.52M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Springer Timothy A
4.42M
23.68%
+196.29K
+4.64%
Apr 11, 2025
Fidelity Management & Research Company LLC
2.80M
14.99%
+1.28M
+84.63%
Mar 31, 2025
Deep Track Capital LP
1.40M
7.51%
--
--
Mar 31, 2025
TAS Partners, L.L.C.
1.38M
7.41%
+412.50K
+42.52%
Apr 03, 2025
EcoR1 Capital, LLC
935.12K
5.01%
+85.98K
+10.13%
Mar 31, 2025
Farallon Capital Management, L.L.C.
853.05K
4.57%
+140.00K
+19.63%
Mar 31, 2025
Polaris Partners
657.98K
3.52%
-500.00K
-43.18%
Apr 03, 2025
5AM Ventures
511.66K
2.74%
-85.00K
-14.25%
Mar 31, 2025
Prosight Capital
398.88K
2.14%
+398.88K
--
Mar 31, 2025
The Vanguard Group, Inc.
361.17K
1.93%
+120.00
+0.03%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.8%
iShares Micro-Cap ETF
0.05%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares Biotechnology ETF
0.02%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比0.8%
iShares Micro-Cap ETF
占比0.05%
Invesco Nasdaq Biotechnology ETF
占比0.04%
ProShares Ultra Nasdaq Biotechnology
占比0.04%
iShares Biotechnology ETF
占比0.02%
Global X Russell 2000 ETF
占比0.01%
ProShares Hedge Replication ETF
占比0.01%
iShares Russell 2000 Value ETF
占比0.01%
iShares Russell 2000 ETF
占比0.01%
Proshares Ultra Russell 2000
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Jun 18, 2024
Merger
12<1
Jun 18, 2024
Merger
12<1
Jun 18, 2024
Merger
12<1
Jun 18, 2024
Merger
12<1
公告日期
类型
比率
Jun 18, 2024
Merger
12<1
Jun 18, 2024
Merger
12<1
Jun 18, 2024
Merger
12<1
Jun 18, 2024
Merger
12<1
